

Data Safety Monitoring Board Communication

Date: 18 February 2014

TO: TIRCON2012V1 study Investigators

FROM: Dr. Anna Rozova, Director, Medical Safety, ApoPharma Inc.

RE: Clinical study protocol, TIRCON2012V1: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate-kinase associated neurodegeneration (PKAN)

DSMB safety review meeting of 10 February 2014

The second interim review meeting of the independent Data Safety Monitoring Board (DSMB) for the clinical study, TIRCON2012V1, was held on the 10th of February 2014.

The meeting was scheduled and held according to the planned periodic review of safety data. The review encompassed the safety data collected from the beginning of the study until the cut-off period of 09 January 2014 and any late-breaking safety information received between the cut-off point and the date of the meeting.

The DSMB reviewed the above-referenced data and unanimously recommended the continuation of the trial without modification. The DSMB did not identify any issues requiring premature unblinding, suspension or termination of the study.

The next planned interim review meeting will be in August 2014.